TuHURA Biosciences (HURA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Jul, 2026Executive summary
Annual meeting scheduled for August 18, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials online and can request paper or email copies at no charge.
Voting matters and shareholder proposals
Election of six directors to serve until the 2027 annual meeting or until successors are qualified.
Approval sought for issuance of 1,878,287 shares of common stock under a Fee Letter with Parkview Holdings One LLC.
Advisory vote on executive compensation and on the frequency of future say-on-pay votes.
Ratification of Cherry Bekaert LLP as independent auditor for fiscal year ending December 31, 2026.
Provision for other business to be transacted as may properly come before the meeting.
Board of directors and corporate governance
Six nominees listed for director positions: James A Bianco, James Manuso, Alan List, George Ng, Robert Hoffman, and Craig Tendler.
Latest events from TuHURA Biosciences
- Shareholders to vote on director elections, major share issuance, and executive pay; board recommends approval.HURA
Proxy filing9 Jul 2026 - Shareholders will vote on director elections, share issuance, compensation, and auditor ratification.HURA
Proxy filing26 Jun 2026 - Clinical-stage immuno-oncology firm expands pipeline via merger, but faces ongoing financial and execution risks.HURA
Registration filing22 Jun 2026 - Diversified immuno-oncology pipeline advances amid ongoing losses and high funding needs.HURA
Registration filing22 Jun 2026 - Up to $250M in securities registered, including $50M ATM, to fund oncology pipeline and operations.HURA
Registration filing22 Jun 2026 - Merger completed, cash burn persists, and urgent funding needs threaten going concern.HURA
Q3 20249 Jun 2026 - Phase 3 IFx-2.0 trial and Kineta acquisition drive growth, backed by $36M in new funding.HURA
Q4 20249 Jun 2026 - Net loss widened to $6.7M in Q1 2025; pipeline and merger progress drive outlook.HURA
Q1 20259 Jun 2026 - Net loss rose to $7.1M in Q3 2025 as R&D spending increased and liquidity concerns persist.HURA
Q3 20259 Jun 2026